Purpose Of Review: Addressing cardiometabolic risk factors in persons with serious mental illness requires early screening and proactive medical management in both medical and mental health settings.
Recent Findings: Cardiovascular disease remains the leading cause of death for persons with serious mental illness (SMI), such as schizophrenia or bipolar disorder, much of which is driven by a high prevalence of metabolic syndrome, diabetes, and tobacco use. We summarize barriers and recent approaches to screening and treatment for metabolic cardiovascular risk factors within physical health and specialty mental health settings. Incorporating system-based and provider-level support within physical health and psychiatric clinical settings should contribute to improvement for screening, diagnosis, and treatment for cardiometabolic conditions for patients with SMI. Targeted education for clinicians and leveraging multi-disciplinary teams are important first steps to recognize and treat populations with SMI at risk of CVD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042919 | PMC |
| http://dx.doi.org/10.1007/s11886-023-01848-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Stories of taking part in Everyday Life Rehabilitation - A narrative inquiry of residents with serious mental illness and their recovery pathway.
AIMS Public Health
December 2024
Department of Epidemiology and Global Health, Umeå University, Umeå, Sweden.
Context And Purpose: Persons enduring serious mental illness (SMI) and living in supported housing facilities often receive inadequate care, which can negatively impact their health outcomes. To address these challenges, it is crucial to prioritize interventions that promote personal recovery and address the unique needs of this group. When developing effective, equitable, and relevant interventions, it is essential to consider the experiences of persons with an SMI.
View Article and Find Full Text PDFEvaluation of the effectiveness of a serious game titled "Kookism" on the receptive lexicon in 4-9-year-old autistic children.
Heliyon
January 2025
Department of Clinical Psychology, School of Behavioral Sciences and Mental Health (Tehran Institute of Psychiatry), Iran University of Mental Science, Tehran, Iran.
Background: Autistic children often face difficulties with semantic skills such as receptive lexicon. Games based on behavioral principles have been emphasized for treating autistic children. Serious Games are a new and effective way to alleviate deficits in autistic children.
View Article and Find Full Text PDFPsychological Status and its Influencing Factors of Staff in a District of Shenzhen: A Retrospective Study.
Actas Esp Psiquiatr
January 2025
Department of Chronic Disease, Longhua District Center for Chronic Disease Control/Mental Health, 510080 Shenzhen, Guangdong, China.
Background: Anxiety, depression, and sleep disorders, as psychological and emotional diseases, have serious impact on people's physical and mental health, and receive increasing academic attention. This study aimed to examine anxiety, depression, and sleep disorder of staff in a district of Shenzhen and to provide the basis for the development of targeted intervention measures to improve the psychological status of cadres.
Methods: Based on the psychological evaluation data of staff cadres in a district of Shenzhen City obtained from January to December 2020, a stratified sampling method was adopted to randomly select two streets and three communities in each street.
Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial.
J Prev Alzheimers Dis
January 2025
Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA. Electronic address:
Background: There are no approved oral disease-modifying treatments for Alzheimer's disease (AD).
Objectives: The objective of this study was to assess efficacy and safety of blarcamesine (ANAVEX®2-73), an orally available small-molecule activator of the sigma-1 receptor (SIGMAR1) in early AD through restoration of cellular homeostasis including autophagy enhancement.
Design: ANAVEX2-73-AD-004 was a randomized, double-blind, placebo-controlled, 48-week Phase IIb/III trial.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!